Literature DB >> 1824371

Development, production and pharmacodynamics of human growth hormone.

J T Jørgensen1, T Chirstensen, M Jørgensen, G Jakobsen.   

Abstract

With the advent of recombinant DNA technology, it is possible to produce biosynthetic human growth hormone (B-hGH). Novo Nordisk A/S has developed a method for manufacturing B-hGH which is identical to the 22K fraction of pituitary human growth hormone (P-hGH), using a nonpathogenic strain of Escherichia coli as host. B-hGH has been investigated extensively in physical, chemical and biological studies and found to be identical to P-hGH. Pharmacological studies have revealed that B-hGH possesses the same pharmacokinetic and short-term metabolic profiles as P-hGH. Long term clinical studies have shown that B-hGH induces a significant increase in height velocity in children with growth hormone deficiency (GHD) and is characterized by a low antigenicity.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1824371     DOI： 10.1007/bf02750980

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


  11 in total

1.  Treatment of a pituitary dwarf with human growth hormone.

Authors:  M S RABEN
Journal:  J Clin Endocrinol Metab       Date:  1958-08       Impact factor: 5.958

2.  Serum profiles and short-term metabolic effect of pituitary and authentic biosynthetic human growth hormone in man. A double-blind cross-over study.

Authors:  J O Jørgensen; A Flyvbjerg; J Dinesen; H Lund; K G Alberti; H Orskov; J S Christiansen
Journal:  Acta Endocrinol (Copenh)       Date:  1987-11

3.  Long-term response to human growth hormone in 36 children with idiopathic growth hormone deficiency.

Authors:  M Ranke; B Weber; J R Bierich
Journal:  Eur J Pediatr       Date:  1979       Impact factor: 3.183

4.  Authentic recombinant human growth hormone. Results of a multicenter clinical trial in patients with growth hormone deficiency.

Authors:  L H Rasmussen; M Zachmann; P Nilsson
Journal:  Helv Paediatr Acta       Date:  1989-06

5.  Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children.

Authors:  K W Kastrup; J S Christiansen; J K Andersen; H Orskov
Journal:  Acta Endocrinol (Copenh)       Date:  1983-10

6.  Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites.

Authors:  J O Jørgensen; N Møller; T Lauritzen; K G Alberti; H Orskov; J S Christiansen
Journal:  J Clin Endocrinol Metab       Date:  1990-01       Impact factor: 5.958

7.  Treatment of pituitary dwarfism with methionyl human growth hormone in Japan.

Authors:  K Takano; K Shizume; N Hizuka; A Okuno; T Umino; Y Kobayashi; S Kusano; H Nakajima; M Irie; I Hibi
Journal:  Endocrinol Jpn       Date:  1986-10

8.  Comparison of the pharmacological properties of pituitary and biosynthetic human growth hormone. Demonstration of antinatriuretic/antidiuretic and barbital sleep effects of human growth hormone in rats.

Authors:  K D Jørgensen
Journal:  Acta Endocrinol (Copenh)       Date:  1987-01

9.  Long term effects of human growth hormone on 1,959 patients with pituitary dwarfism throughout Japan.

Authors:  K Shizume
Journal:  Endocrinol Jpn       Date:  1984-04

10.  Subcutaneous versus intramuscular growth hormone therapy: growth and acute somatomedin response.

Authors:  D M Wilson; B Baker; R L Hintz; R G Rosenfeld
Journal:  Pediatrics       Date:  1985-09       Impact factor: 7.124
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.